Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.

Diop F, Moia R, Favini C, Spaccarotella E, De Paoli L, Bruscaggin A, Spina V, Terzi-di-Bergamo L, Arruga F, Tarantelli C, Deambrogi C, Rasi S, Adhinaveni R, Patriarca A, Favini S, Sagiraju S, Jabangwe C, Kodipad AA, Peroni D, Mauro FR, Del Giudice I, Forconi F, Cortelezzi A, Zaja F, Bomben R, Rossi FM, Visco C, Chiarenza A, Rigolin GM, Marasca R, Coscia M, Perbellini O, Tedeschi A, Laurenti L, Motta M, Donaldson D, Weir P, Mills K, Thornton P, Lawless S, Bertoni F, Del Poeta G, Cuneo A, Follenzi A, Gattei V, Boldorini RL, Catherwood M, Deaglio S, Foá R, Gaidano G, Rossi D.

Haematologica. 2019 Aug 1. pii: haematol.2019.219550. doi: 10.3324/haematol.2019.219550. [Epub ahead of print]

2.

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.

Larocca A, Mina R, Offidani M, Liberati AM, Ledda A, Patriarca F, Evangelista A, Spada S, Benevolo G, Oddolo D, Innao V, Cangialosi C, Bernardini A, Musto P, Amico V, Fraticelli V, Paris L, Giuliani N, Falcone AP, Zambello R, De Paoli L, Romano A, Palumbo A, Montefusco V, Hajek R, Boccadoro M, Bringhen S.

Haematologica. 2019 Jun 27. pii: haematol.2019.220657. doi: 10.3324/haematol.2019.220657. [Epub ahead of print]

3.

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.

Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R, Musolino C, Patriarca F, Musto P, Galieni P, Ballanti S, Nozzoli C, Cascavilla N, Ben-Yehuda D, Nagler A, Hajek R, Offidani M, Liberati AM, Sonneveld P, Cavo M, Corradini P, Boccadoro M.

Haematologica. 2019 Jun 20. pii: haematol.2019.219139. doi: 10.3324/haematol.2019.219139. [Epub ahead of print]

4.

Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML.

Bassan R, Intermesoli T, Masciulli A, Pavoni C, Boschini C, Gianfaldoni G, Marmont F, Cavattoni I, Mattei D, Terruzzi E, De Paoli L, Cattaneo C, Borlenghi E, Ciceri F, Bernardi M, Scattolin AM, Todisco E, Campiotti L, Corradini P, Cortelezzi A, Ferrero D, Zanghì P, Oldani E, Spinelli O, Audisio E, Cortelazzo S, Bosi A, Falini B, Pogliani EM, Rambaldi A.

Blood Adv. 2019 Apr 9;3(7):1103-1117. doi: 10.1182/bloodadvances.2018026625.

5.

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.

Saltarella I, Morabito F, Giuliani N, Terragna C, Omedè P, Palumbo A, Bringhen S, De Paoli L, Martino E, Larocca A, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Dammacco F, Boccadoro M, Vacca A, Ria R.

J Hematol Oncol. 2019 Jan 9;12(1):4. doi: 10.1186/s13045-018-0691-4.

6.

Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials.

D'Agostino M, De Paoli L, Conticello C, Offidani M, Ria R, Petrucci MT, Spada S, Marcatti M, Catalano L, Gilestro M, Guglielmelli T, Baldini L, Gamberi B, Rizzi R, De Sabbata G, Di Renzo N, Patriarca F, Pezzatti S, Siniscalchi A, Ribolla R, Palumbo A, Montefusco V, Nagler A, Boccadoro M, Gay F.

Crit Rev Oncol Hematol. 2018 Dec;132:9-16. doi: 10.1016/j.critrevonc.2018.09.008. Epub 2018 Sep 14. Review.

PMID:
30447931
7.

Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.

Mina R, Petrucci MT, Corradini P, Spada S, Patriarca F, Cerrato C, De Paoli L, Pescosta N, Ria R, Malfitano A, Musto P, Baldini L, Guglielmelli T, Gamberi B, Mannina D, Benevolo G, Zambello R, Falcone AP, Palumbo A, Nagler A, Calafiore V, Hájek R, Spencer A, Boccadoro M, Bringhen S.

Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):533-540. doi: 10.1016/j.clml.2018.05.019. Epub 2018 May 28.

PMID:
29910180
8.

Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis.

Cerrato C, Di Raimondo F, De Paoli L, Spada S, Patriarca F, Crippa C, Mina R, Guglielmelli T, Ben-Yehuda D, Oddolo D, Nozzoli C, Angelucci E, Cascavilla N, Rizzi R, Rocco S, Baldini L, Ponticelli E, Marcatti M, Cangialosi C, Caravita T, Benevolo G, Ria R, Nagler A, Musto P, Tacchetti P, Corradini P, Offidani M, Palumbo A, Petrucci MT, Boccadoro M, Gay F.

J Cancer Res Clin Oncol. 2018 Jul;144(7):1357-1366. doi: 10.1007/s00432-018-2641-5. Epub 2018 Apr 19.

PMID:
29675792
9.

Access to health services for the refugee community in Greece: lessons learned.

De Paoli L.

Public Health. 2018 Apr;157:104-106. doi: 10.1016/j.puhe.2018.01.011. Epub 2018 Mar 20. No abstract available.

PMID:
29501983
10.

Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study.

Bringhen S, Mina R, Cafro AM, Liberati AM, Spada S, Belotti A, Gaidano G, Patriarca F, Troia R, Fanin R, De Paoli L, Rossi G, Lombardo A, Bertazzoni P, Palumbo A, Sonneveld P, Boccadoro M.

Leukemia. 2018 Aug;32(8):1803-1807. doi: 10.1038/s41375-018-0024-1. Epub 2018 Jan 30. No abstract available.

PMID:
29479061
11.

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.

Bringhen S, D'Agostino M, De Paoli L, Montefusco V, Liberati AM, Galieni P, Grammatico S, Muccio VE, Esma F, De Angelis C, Musto P, Ballanti S, Offidani M, Petrucci MT, Gaidano G, Corradini P, Palumbo A, Sonneveld P, Boccadoro M.

Leukemia. 2018 Apr;32(4):979-985. doi: 10.1038/leu.2017.327. Epub 2017 Nov 16.

PMID:
29263440
12.

Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up.

Ghione P, Genuardi E, Rossi D, Drandi D, Mantoan B, Barbero D, Bernocco E, Monitillo L, Cerri M, Ruggeri M, Omede P, Deambrogi C, De Paoli L, Passera R, Coscia M, Cavallo F, Massaia M, Boccadoro M, Gaidano G, Ladetto M, Ferrero S.

Br J Haematol. 2018 Jun;181(5):693-695. doi: 10.1111/bjh.14681. Epub 2017 Apr 2. No abstract available.

PMID:
28369711
13.

Chronic lymphocytic leukaemia: a step ahead in the journey toward eradication.

De Paoli L, Gaidano G.

Lancet Oncol. 2017 Feb;18(2):163-164. doi: 10.1016/S1470-2045(17)30017-7. Epub 2017 Jan 13. No abstract available.

PMID:
28089631
14.

A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma.

Larocca A, Bringhen S, Petrucci MT, Oliva S, Falcone AP, Caravita T, Villani O, Benevolo G, Liberati AM, Morabito F, Montefusco V, Passera R, De Rosa L, Omedé P, Vincelli ID, Spada S, Carella AM, Ponticelli E, Derudas D, Genuardi M, Guglielmelli T, Nozzoli C, Aghemo E, De Paoli L, Conticello C, Musolino C, Offidani M, Boccadoro M, Sonneveld P, Palumbo A.

Leukemia. 2016 Jun;30(6):1320-6. doi: 10.1038/leu.2016.36. Epub 2016 Feb 22.

15.

Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia.

Rasi S, Khiabanian H, Ciardullo C, Terzi-di-Bergamo L, Monti S, Spina V, Bruscaggin A, Cerri M, Deambrogi C, Martuscelli L, Biasi A, Spaccarotella E, De Paoli L, Gattei V, Foà R, Rabadan R, Gaidano G, Rossi D.

Haematologica. 2016 Apr;101(4):e135-8. doi: 10.3324/haematol.2015.136051. Epub 2016 Jan 27. No abstract available.

16.

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.

Magarotto V, Bringhen S, Offidani M, Benevolo G, Patriarca F, Mina R, Falcone AP, De Paoli L, Pietrantuono G, Gentili S, Musolino C, Giuliani N, Bernardini A, Conticello C, Pulini S, Ciccone G, Maisnar V, Ruggeri M, Zambello R, Guglielmelli T, Ledda A, Liberati AM, Montefusco V, Hajek R, Boccadoro M, Palumbo A.

Blood. 2016 Mar 3;127(9):1102-8. doi: 10.1182/blood-2015-08-662627. Epub 2016 Jan 4. Erratum in: Blood. 2018 Mar 29;131(13):1495.

17.

Imaging characteristics of pleural tumours.

De Paoli L, Quaia E, Poillucci G, Gennari A, Cova MA.

Insights Imaging. 2015 Dec;6(6):729-40. doi: 10.1007/s13244-015-0441-x. Epub 2015 Oct 16.

18.

A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients.

Tedeschi A, Rossi D, Motta M, Quaresmini G, Rossi M, Coscia M, Anastasia A, Rossini F, Cortelezzi A, Nador G, Scarfò L, Cairoli R, Frustaci AM, Dalceggio D, Picardi P, De Paoli L, Orlandi E, Rambaldi A, Massaia M, Gaidano G, Montillo M; Rete Ematologica Lombarda–CLL Workgroup.

Haematologica. 2015 Dec;100(12):e501-4. doi: 10.3324/haematol.2015.132035. Epub 2015 Aug 20. No abstract available.

19.

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.

Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, Bulian P, Visco C, Mauro FR, Morabito F, Cortelezzi A, Zaja F, Forconi F, Laurenti L, Del Giudice I, Gentile M, Vincelli I, Motta M, Coscia M, Rigolin GM, Tedeschi A, Neri A, Marasca R, Perbellini O, Moreno C, Del Poeta G, Massaia M, Zinzani PL, Montillo M, Cuneo A, Gattei V, Foà R, Gaidano G.

Blood. 2015 Oct 15;126(16):1921-4. doi: 10.1182/blood-2015-05-647925. Epub 2015 Aug 14.

20.

Fistulojejunostomy for refractory post-traumatic biliary fistula in an austere environment: an unusual, time-honored procedure.

Kada F, Abyad M, Contini S, De Paoli L, Mancini L.

J Am Coll Surg. 2015 May;220(5):e61-3. doi: 10.1016/j.jamcollsurg.2015.01.022. Epub 2015 Feb 4. Review. No abstract available.

PMID:
25840547
21.

Towards tuberculosis elimination: an action framework for low-incidence countries.

Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, Goletti D, González Ochoa ER, LoBue P, Matteelli A, Njoo H, Solovic I, Story A, Tayeb T, van der Werf MJ, Weil D, Zellweger JP, Abdel Aziz M, Al Lawati MR, Aliberti S, Arrazola de Oñate W, Barreira D, Bhatia V, Blasi F, Bloom A, Bruchfeld J, Castelli F, Centis R, Chemtob D, Cirillo DM, Colorado A, Dadu A, Dahle UR, De Paoli L, Dias HM, Duarte R, Fattorini L, Gaga M, Getahun H, Glaziou P, Goguadze L, Del Granado M, Haas W, Järvinen A, Kwon GY, Mosca D, Nahid P, Nishikiori N, Noguer I, O'Donnell J, Pace-Asciak A, Pompa MG, Popescu GG, Robalo Cordeiro C, Rønning K, Ruhwald M, Sculier JP, Simunović A, Smith-Palmer A, Sotgiu G, Sulis G, Torres-Duque CA, Umeki K, Uplekar M, van Weezenbeek C, Vasankari T, Vitillo RJ, Voniatis C, Wanlin M, Raviglione MC.

Eur Respir J. 2015 Apr;45(4):928-52. doi: 10.1183/09031936.00214014. Review.

22.

Analysis of human β-papillomavirus and Merkel cell polyomavirus infection in skin lesions and eyebrow hair bulbs from a cohort of patients with chronic lymphocytic leukaemia.

Peretti A, Borgogna C, Rossi D, De Paoli L, Bawadekar M, Zavattaro E, Boldorini R, De Andrea M, Gaidano G, Gariglio M.

Br J Dermatol. 2014 Dec;171(6):1525-8. doi: 10.1111/bjd.13215. Epub 2014 Oct 26.

23.

Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.

Montillo M, Tedeschi A, Gaidano G, Coscia M, Petrizzi VB, Orlandi E, Cascavilla N, Ghia P, Motta M, Gallamini A, Frustaci AM, Rossi D, De Paoli L, Nichelatti M, Morra E, Massaia M.

Haematologica. 2014 Sep;99(9):e159-61. doi: 10.3324/haematol.2014.106740. Epub 2014 Jun 27. No abstract available.

24.

Predictors of mesorectal fascia invasion after gadolinium injection in rectal carcinoma after neoadjuvant therapy.

Quaia E, Gennari AG, De Paoli L, Angileri R, Ukmar M, Cova MA.

Clin Imaging. 2014 Sep-Oct;38(5):698-703. doi: 10.1016/j.clinimag.2014.05.003. Epub 2014 May 16.

PMID:
24934670
25.

Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.

Rossi D, Khiabanian H, Spina V, Ciardullo C, Bruscaggin A, Famà R, Rasi S, Monti S, Deambrogi C, De Paoli L, Wang J, Gattei V, Guarini A, Foà R, Rabadan R, Gaidano G.

Blood. 2014 Apr 3;123(14):2139-47. doi: 10.1182/blood-2013-11-539726. Epub 2014 Feb 5.

26.

Indeterminate solid hepatic lesions identified on non-diagnostic contrast-enhanced computed tomography: assessment of the additional diagnostic value of contrast-enhanced ultrasound in the non-cirrhotic liver.

Quaia E, De Paoli L, Angileri R, Cabibbo B, Cova MA.

Eur J Radiol. 2014 Mar;83(3):456-62. doi: 10.1016/j.ejrad.2013.12.012. Epub 2013 Dec 16.

PMID:
24387826
27.

Evidence of diagnostic enhancement pattern in hepatocellular carcinoma nodules ≤2 cm according to the AASLD/EASL revised criteria.

Quaia E, De Paoli L, Angileri R, Pizzolato R, Cabibbo B, Cova MA.

Abdom Imaging. 2013 Dec;38(6):1245-53. doi: 10.1007/s00261-013-0031-7.

PMID:
24026173
28.

Predictors of dysplastic nodule diagnosis in patients with liver cirrhosis on unenhanced and gadobenate dimeglumine-enhanced MRI with dynamic and hepatobiliary phase.

Quaia E, De Paoli L, Pizzolato R, Angileri R, Pantano E, Degrassi F, Ukmar M, Cova MA.

AJR Am J Roentgenol. 2013 Mar;200(3):553-62. doi: 10.2214/AJR.12.8818.

PMID:
23436844
29.

The value of time-intensity curves obtained after microbubble contrast agent injection to discriminate responders from non-responders to anti-inflammatory medication among patients with Crohn's disease.

Quaia E, Cabibbo B, De Paoli L, Toscano W, Poillucci G, Cova MA.

Eur Radiol. 2013 Jun;23(6):1650-9. doi: 10.1007/s00330-012-2754-1. Epub 2013 Jan 10.

PMID:
23306710
30.

Arterial enhancing-only nodules less than 2 cm in diameter in patients with liver cirrhosis: predictors of hepatocellular carcinoma diagnosis on gadobenate dimeglumine-enhanced MR imaging.

Quaia E, Pizzolato R, De Paoli L, Angileri R, Ukmar M, Cova MA.

J Magn Reson Imaging. 2013 Apr;37(4):892-902. doi: 10.1002/jmri.23873. Epub 2012 Oct 23.

PMID:
23097278
31.

MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia.

De Paoli L, Cerri M, Monti S, Rasi S, Spina V, Bruscaggin A, Greco M, Ciardullo C, Famà R, Cresta S, Maffei R, Ladetto M, Martini M, Laurenti L, Forconi F, Marasca R, Larocca LM, Bertoni F, Gaidano G, Rossi D.

Leuk Lymphoma. 2013 May;54(5):1087-90. doi: 10.3109/10428194.2012.723706. Epub 2012 Nov 12. No abstract available.

PMID:
23039309
32.

Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients.

Falco P, Cavallo F, Larocca A, Rossi D, Guglielmelli T, Rocci A, Grasso M, Siez ML, De Paoli L, Oliva S, Molica S, Mina R, Gay F, Benevolo G, Musto P, Omedè P, Freilone R, Bringhen S, Carella AM, Gaidano G, Boccadoro M, Palumbo A.

Leukemia. 2013 Mar;27(3):695-701. doi: 10.1038/leu.2012.271. Epub 2012 Sep 21.

PMID:
22996335
33.

The value of small bowel wall contrast enhancement after sulfur hexafluoride-filled microbubble injection to differentiate inflammatory from fibrotic strictures in patients with Crohn's disease.

Quaia E, De Paoli L, Stocca T, Cabibbo B, Casagrande F, Cova MA.

Ultrasound Med Biol. 2012 Aug;38(8):1324-32. doi: 10.1016/j.ultrasmedbio.2012.04.008. Epub 2012 Jun 13.

PMID:
22698508
34.

Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F, Marasca R, Laurenti L, Bruscaggin A, Cerri M, Monti S, Cresta S, Famà R, De Paoli L, Bulian P, Gattei V, Guarini A, Deaglio S, Capello D, Rabadan R, Pasqualucci L, Dalla-Favera R, Foà R, Gaidano G.

Blood. 2012 Jan 12;119(2):521-9. doi: 10.1182/blood-2011-09-379966. Epub 2011 Nov 10.

35.
36.

Saliva is a reliable and practical source of germline DNA for genome-wide studies in chronic lymphocytic leukemia.

Rasi S, Bruscaggin A, Rinaldi A, Cresta S, Fangazio M, De Paoli L, Monti S, Gargiulo E, Kwee I, Foà R, Bertoni F, Gaidano G, Rossi D.

Leuk Res. 2011 Oct;35(10):1419-22. doi: 10.1016/j.leukres.2011.05.024. Epub 2011 Jun 12.

PMID:
21663967
37.

Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.

Corsetti MT, Salvi F, Perticone S, Baraldi A, De Paoli L, Gatto S, Pietrasanta D, Pini M, Primon V, Zallio F, Tonso A, Alvaro MG, Ciravegna G, Levis A.

Leuk Res. 2011 Aug;35(8):991-7. doi: 10.1016/j.leukres.2011.02.021. Epub 2011 Apr 6.

PMID:
21474179
38.

Predictive markers and driving factors behind Richter syndrome development.

Fangazio M, De Paoli L, Rossi D, Gaidano G.

Expert Rev Anticancer Ther. 2011 Mar;11(3):433-42. doi: 10.1586/era.10.237. Review.

PMID:
21417856
39.

Progressive multifocal leucoencephalopathy after autologous bone marrow transplantation: a treatment option.

Ripellino P, Comi C, Mula M, Varrasi C, Conconi A, Stecco A, Brustia D, Nasuelli N, Savio K, De Paoli L, Cantello R, Gaidano G, Monaco F.

BMJ Case Rep. 2011 Apr 15;2011. pii: bcr1120103549. doi: 10.1136/bcr.11.2010.3549.

40.

The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma.

Rossi D, Rasi S, Di Rocco A, Fabbri A, Forconi F, Gloghini A, Bruscaggin A, Franceschetti S, Fangazio M, De Paoli L, Bruna R, Capello D, Chiappella A, Lobetti Bodoni C, Giachelia M, Tisi MC, Pogliani EM, Lauria F, Ladetto M, Hohaus S, Martelli M, Vitolo U, Carbone A, Foà R, Gaidano G.

Blood. 2011 Feb 24;117(8):2405-13. doi: 10.1182/blood-2010-07-296244. Epub 2010 Dec 14.

41.

A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome.

Rasi S, Spina V, Bruscaggin A, Vaisitti T, Tripodo C, Forconi F, De Paoli L, Fangazio M, Sozzi E, Cencini E, Laurenti L, Marasca R, Visco C, Xu-Monette ZY, Gattei V, Young KH, Malavasi F, Deaglio S, Gaidano G, Rossi D.

Br J Haematol. 2011 Feb;152(3):284-94. doi: 10.1111/j.1365-2141.2010.08482.x. Epub 2010 Dec 1.

PMID:
21121903
42.

Low CD49d expression and long telomere identify a chronic lymphocytic leukemia subset with highly favourable outcome.

Rossi D, Bodoni CL, Zucchetto A, Rasi S, De Paoli L, Fangazio M, Rossi FM, Ladetto M, Gattei V, Gaidano G.

Am J Hematol. 2010 Aug;85(8):619-22. doi: 10.1002/ajh.21756. No abstract available.

43.

Analysis of the REL, BCL11A, and MYCN proto-oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia.

Deambrogi C, De Paoli L, Fangazio M, Cresta S, Rasi S, Spina V, Gattei V, Gaidano G, Rossi D.

Am J Hematol. 2010 Jul;85(7):541-4. doi: 10.1002/ajh.21742. No abstract available.

44.

BCL3 translocation in CLL with typical phenotype: assessment of frequency, association with cytogenetic subgroups, and prognostic significance.

Rossi D, Deambrogi C, Monti S, Cresta S, De Paoli L, Fangazio M, Giardini I, Bernasconi P, Gaidano G.

Br J Haematol. 2010 Sep;150(6):702-4. doi: 10.1111/j.1365-2141.2010.08255.x. No abstract available.

PMID:
20553272
45.

Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma.

Rossi D, Fangazio M, De Paoli L, Puma A, Riccomagno P, Pinto V, Zigrossi P, Ramponi A, Monga G, Gaidano G.

Cancer. 2010 May 1;116(9):2188-200. doi: 10.1002/cncr.24959.

46.

Derivative (1)t(1;16)(p11;p11.1) in myelodysplastic syndrome: a case report and review of the literature.

Lunghi M, Casorzo L, De Paoli L, Riccomagno P, Rossi D, Gaidano G.

Cancer Genet Cytogenet. 2010 Jan 1;196(1):89-92. doi: 10.1016/j.cancergencyto.2009.07.003. Review.

PMID:
19963141
47.

Monitoring of cytomegalovirus reactivation during induction and nontransplant consolidation of acute leukemia.

Lunghi M, Riccomagno P, De Paoli L, Vendramin C, Conconi A, Gaidano G, Rossi D.

Am J Hematol. 2009 Oct;84(10):697-8. doi: 10.1002/ajh.21494. No abstract available.

48.

Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome.

Rossi D, Spina V, Cerri M, Rasi S, Deambrogi C, De Paoli L, Laurenti L, Maffei R, Forconi F, Bertoni F, Zucca E, Agostinelli C, Cabras A, Lucioni M, Martini M, Magni M, Deaglio S, Ladetto M, Nomdedeu JF, Besson C, Ramponi A, Canzonieri V, Paulli M, Marasca R, Larocca LM, Carbone A, Pileri SA, Gattei V, Gaidano G.

Clin Cancer Res. 2009 Jul 1;15(13):4415-22. doi: 10.1158/1078-0432.CCR-08-3266. Epub 2009 Jun 9.

49.

Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21.

Rossi D, Rasi S, Franceschetti S, Capello D, Castelli A, De Paoli L, Ramponi A, Chiappella A, Pogliani EM, Vitolo U, Kwee I, Bertoni F, Conconi A, Gaidano G.

Leukemia. 2009 Jun;23(6):1118-26. doi: 10.1038/leu.2008.398. Epub 2009 Jan 29.

PMID:
19448608
50.

The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors.

Rossi D, Sozzi E, Puma A, De Paoli L, Rasi S, Spina V, Gozzetti A, Tassi M, Cencini E, Raspadori D, Pinto V, Bertoni F, Gattei V, Lauria F, Gaidano G, Forconi F.

Br J Haematol. 2009 Jun;146(1):64-75. doi: 10.1111/j.1365-2141.2009.07711.x. Epub 2009 May 5.

PMID:
19438485

Supplemental Content

Loading ...
Support Center